Market Research Logo

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018, provides an overview of the Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline landscape.

Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 4, 20 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively.

Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Muscular Atrophy (SMA) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Muscular Atrophy (SMA) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Muscular Atrophy (SMA) (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Muscular Atrophy (SMA) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Muscular Atrophy (SMA) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Spinal Muscular Atrophy (SMA) - Overview
Spinal Muscular Atrophy (SMA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinal Muscular Atrophy (SMA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinal Muscular Atrophy (SMA) - Companies Involved in Therapeutics Development
AndroScience Corp
AveXis Inc
Biogen Inc
BioMarin Pharmaceutical Inc
Cytokinetics Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Genethon SA
Ionis Pharmaceuticals Inc
Kowa Co Ltd
Neurodyn Life Sciences Inc
Neurotune AG
Novartis AG
Ono Pharmaceutical Co Ltd
Paratek Pharmaceuticals Inc
Recursion Pharmaceuticals Inc
Sarepta Therapeutics Inc
Scholar Rock Inc
Spotlight Innovation Inc
Vybion Inc
Spinal Muscular Atrophy (SMA) - Drug Profiles
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALB-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALG-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amifampridine phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASC-J9/ASC-JM.X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASCJ-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIIB-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
branaplam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LDN-5178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maresin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onasemnogene abeparvovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMO-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTKSMA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0000716 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REC-0001202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reldesemtiv - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
risdiplam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rycal - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit GSK-3 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 2 to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Kennedy's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for X-Linked Infantile Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate SMN2 for Spinal Muscular Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SRSF10 and BCLAF1 for HIV Infection, Spinal Muscular Atrophy and Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SMN-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STL-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valproate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xcel-hNu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xcel-hNuP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Spinal Muscular Atrophy (SMA) - Dormant Projects
Spinal Muscular Atrophy (SMA) - Discontinued Products
Spinal Muscular Atrophy (SMA) - Product Development Milestones
Featured News & Press Releases
Jul 24, 2018: Spotlight Innovation spinal muscular atrophy research collaborator professor Kevin Hodgetts receives $300,000 grant from Cure SMA
Jun 16, 2018: Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
Jun 14, 2018: Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas
Jun 08, 2018: Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
May 31, 2018: Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
May 08, 2018: AveXis Issues Community Statement on the SPR1NT Trial
Apr 25, 2018: AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
Apr 24, 2018: AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
Apr 19, 2018: AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
Mar 29, 2018: Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy
Mar 27, 2018: AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
Mar 13, 2018: Newly Issued U.S. Patent Covers Spotlight Innovations Spinal Muscular Atrophy Drug Candidates
Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018
Feb 02, 2018: Scholar Rock Announces Publication of Comprehensive Pharmacological Study of SRK-015, a Novel Inhibitor of Myostatin Activation, Supporting the Treatment of Muscle Atrophy Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Spinal Muscular Atrophy (SMA), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by AndroScience Corp, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by AveXis Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Biogen Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by BioMarin Pharmaceutical Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Cytokinetics Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Exicure Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Genethon SA, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Kowa Co Ltd, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Neurodyn Life Sciences Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Neurotune AG, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Novartis AG, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Paratek Pharmaceuticals Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Recursion Pharmaceuticals Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Sarepta Therapeutics Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Scholar Rock Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Spotlight Innovation Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Pipeline by Vybion Inc, H2 2018
Spinal Muscular Atrophy (SMA) - Dormant Projects, H2 2018
Spinal Muscular Atrophy (SMA) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Spinal Muscular Atrophy (SMA) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Spinal Muscular Atrophy (SMA), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report